Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Bicarbonate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLA | P06280 | 1/20 | 0.67 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.53 |
| ▸ | CHRM2 | P08172 | 6/20 | 0.51 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.51 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.50 |
| ▸ | BCHE | P06276 | 1/20 | 0.50 |
| ▸ | ACHE | P22303 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bicarbonate SCHEMBL1720584 | 1.00 | GLA (0.67) | GLATSHRRXFP1CYP2D6CHRM2 | |
| Benzoclidine SCHEMBL1542430 | 0.83 | GLA (0.74) | GLATSHRRXFP1CYP2D6CHRM2 | |
| Benzoclidine SCHEMBL342347 | 0.83 | GLA (0.74) | GLATSHRRXFP1CYP2D6CHRM2 | |
| Benzoclidine SCHEMBL1542330 | 0.83 | GLA (0.74) | GLATSHRRXFP1CYP2D6CHRM2 | |
| SCHEMBL12615276 | 0.76 | NTMT1 (0.56) | CHRNA7BCHEACHE | |
| SCHEMBL28547261 | 0.76 | CHRM2 (0.75) | CYP2D6CHRM2CHRM1CHRM3 | |
| SCHEMBL14808302 | 0.75 | ALDH1A1 (0.69) | GLATSHRMEN1KMT2AGAA | |
| SCHEMBL13185203 | 0.75 | LSS (0.53) | CHRM1CHRNA7 | |
| SCHEMBL13282720 | 0.74 | CHRM3 (0.57) | CYP2D6CHRM2CHRM1CHRM3CHRNA7 | |
| SCHEMBL2485702 | 0.73 | CHRM3 (0.78) | CHRM2CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2406257-B1 | A NEW METHOD FOR THE PREPARATION OF SOLIFENACIN AND NEW INTERMEDIATE THEREOF | MEGAFINE PHARMA P LTD (IN) | 2019-08-07 | — | — | EP | claimed |
| US-8283470-B2 | Method for the preparation of solifenacin and intermediate thereof | MEGAFINE PHARMA(P) LTD. (IN) | 2012-10-09 | — | — | US | claimed |
| US-20110319621-A1 | METHOD FOR THE PREPARATION OF SOLIFENACIN AND INTERMEDIATE THEREOF | MEGAFINE PHARMA(P) LTD. (IN) | 2011-12-29 | — | — | US | claimed |
| EP-2406257-B1 | A NEW METHOD FOR THE PREPARATION OF SOLIFENACIN AND NEW INTERMEDIATE THEREOF | MEGAFINE PHARMA P LTD (IN) | 2019-08-07 | — | — | EP | disclosed |
| US-8283470-B2 | Method for the preparation of solifenacin and intermediate thereof | MEGAFINE PHARMA(P) LTD. (IN) | 2012-10-09 | — | — | US | disclosed |
| EP-2406257-A1 | A NEW METHOD FOR THE PREPARATION OF SOLIFENACIN AND NEW INTERMEDIATE THEREOF | Megafine Pharma (P) Ltd. (IN) | 2012-01-18 | — | — | EP | disclosed |
| US-20110319621-A1 | METHOD FOR THE PREPARATION OF SOLIFENACIN AND INTERMEDIATE THEREOF | MEGAFINE PHARMA(P) LTD. (IN) | 2011-12-29 | — | — | US | disclosed |
| WO-2010103529-A1 | A NEW METHOD FOR THE PREPARATION OF SOLIFENACIN AND NEW INTERMEDIATE THEREOF | MEGAFINE PHARMA(P) LTD. (IN) | 2010-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319621-A1 | METHOD FOR THE PREPARATION OF SOLIFENACIN AND INTERMEDIATE THEREOF | CHRM3, CHRNA1, ADRA1A | GLA 418/4885TSHR 793/4885RXFP1 246/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.